CGEM vs. XNCR, MGNX, BDTX, IPHA, SPPI, CRSP, KRYS, IBRX, IMVT, and DNLI
Should you be buying Cullinan Therapeutics stock or one of its competitors? The main competitors of Cullinan Therapeutics include Xencor (XNCR), MacroGenics (MGNX), Black Diamond Therapeutics (BDTX), Innate Pharma (IPHA), Spectrum Pharmaceuticals (SPPI), CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), ImmunityBio (IBRX), Immunovant (IMVT), and Denali Therapeutics (DNLI). These companies are all part of the "medical" sector.
Xencor (NASDAQ:XNCR) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, community ranking, profitability, institutional ownership, earnings and valuation.
Xencor has higher revenue and earnings than Cullinan Therapeutics. Xencor is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cullinan Therapeutics had 8 more articles in the media than Xencor. MarketBeat recorded 11 mentions for Cullinan Therapeutics and 3 mentions for Xencor. Cullinan Therapeutics' average media sentiment score of 1.33 beat Xencor's score of 0.66 indicating that Xencor is being referred to more favorably in the media.
Xencor has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500.
Cullinan Therapeutics has a net margin of 0.00% compared to Cullinan Therapeutics' net margin of -82.23%. Cullinan Therapeutics' return on equity of -20.29% beat Xencor's return on equity.
86.3% of Cullinan Therapeutics shares are held by institutional investors. 5.2% of Xencor shares are held by insiders. Comparatively, 6.1% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Xencor currently has a consensus price target of $35.43, suggesting a potential upside of 62.96%. Cullinan Therapeutics has a consensus price target of $32.00, suggesting a potential upside of 42.86%. Given Cullinan Therapeutics' higher probable upside, research analysts clearly believe Xencor is more favorable than Cullinan Therapeutics.
Xencor received 455 more outperform votes than Cullinan Therapeutics when rated by MarketBeat users. However, 80.43% of users gave Cullinan Therapeutics an outperform vote while only 72.89% of users gave Xencor an outperform vote.
Summary
Xencor and Cullinan Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Cullinan Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cullinan Therapeutics Competitors List
Related Companies and Tools
